Retatrutide
ALSO SOLD AS LY3437943
Last reviewed 2026-10-30
Our read Opinion
Phase 2 randomized evidence and a phase 3 program support continued development, not routine clinical use. WADA S0 covers this unapproved investigational drug.
- Type
- Investigational (in trials)
- Regulatory status
- Investigational; not FDA-approved
- Compounding status
- Trial use only
- FDA-approved indications
- None
- Evidence level
- Human trials ongoing
- Routes studied
- Injection
- WADA
- Prohibited
- Developer
- Eli Lilly and Company
Claims made by researchers, companies and users. Inclusion does not mean the claim is verified.
- —Early data reported large weight reductions
Agonist at GIP, GLP-1 and glucagon receptors, combining appetite and glucose regulation with glucagon-mediated metabolic effects.
Retatrutide is an investigational triple-receptor agonist in the TRIUMPH clinical program. No approved human indication was verified; trial results do not constitute marketing authorization.
Statuses change; check the linked primary source.
Momentum Opinion
Rising
1 news items in last 30 days
Promising weight-loss results warrant attention, not assumptions of superior long-term safety. Research-market products cannot be equated with the material evaluated in trials.
Company press release
Sponsor reports topline weight-loss outcomes; full data not yet peer reviewed.
Information only. Not medical advice. Listing a compound is not an endorsement or a recommendation to obtain or use it. Ratings and "Our Take" are editorial opinion. Full disclaimer.